SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/2FFAB39D516D68CC633E25CE9E379FDFC6A08F24664D66BDF57FE3735F3390F0A1E7E098AD8A72AC1E6CF11E3E49A62E>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/2FFAB39D516D68CC633E25CE9E379FDFC6A08F24664D66BDF57FE3735F3390F0A1E7E098AD8A72AC1E6CF11E3E49A62E
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/2FFAB39D516D68CC633E25CE9E379FDFC6A08F24664D66BDF57FE3735F3390F0A1E7E098AD8A72AC1E6CF11E3E49A62E
http://www.w3.org/2000/01/rdf-schema#comment
"BCR-ABL activity measured by 50% inhibitory concentration for imatinib p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response"
xsd:string
http://purl.uniprot.org/uniprot/#_A1D1D63B33D42051752F1420DA334AF5E26A7E87D07FD64E7D448C69F6C40A060B0A817ABC9D7B39175504F08F099AB4
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/2FFAB39D516D68CC633E25CE9E379FDFC6A08F24664D66BDF57FE3735F3390F0A1E7E098AD8A72AC1E6CF11E3E49A62E
http://purl.uniprot.org/uniprot/Q9UH97
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/2FFAB39D516D68CC633E25CE9E379FDFC6A08F24664D66BDF57FE3735F3390F0A1E7E098AD8A72AC1E6CF11E3E49A62E
http://purl.uniprot.org/uniprot/#_Q9UH97-mappedCitation-22233112
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/2FFAB39D516D68CC633E25CE9E379FDFC6A08F24664D66BDF57FE3735F3390F0A1E7E098AD8A72AC1E6CF11E3E49A62E